Business Wire

CYNORA

20.1.2021 07:02:08 CET | Business Wire | Press release

Share
CYNORA Announces Availability of Industry’s First Device Test Kits for TADF Deep Green Emitters for Next-Generation OLED Displays

Marking a new innovation trajectory for the OLED industry, CYNORA today announced that device test kits for its Thermally Activated Delayed Fluorescence (TADF)-based Deep Green emitter for next-generation OLED displays are now available to customers. The development is an industry-first milestone for TADF technology, and validates CYNORA’s roadmap commitment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006159/en/

Known as the cyUltimateGreen™, the product delivers efficiency of more than 20 percent, which meets current industry specifications of 150cd/A in top emission devices. It demonstrates lifetime of 400h LT95@15mA, and color point and spectra that match today’s DCI-P3 standard. In addition, the product shows compatibility with BT2020, a color standard that requires greater color purity than DCI-P3, and one that will significantly enlarge the color depth.

The milestone delivers a materials technology breakthrough that will help display manufacturers unleash the full efficiency potential of new-generation OLEDs and catalyze game-changing OLED products. It starts with TADF Deep Green and will soon include a TADF Deep Blue solution.

The cyUltimateGreen Emitter: A “Brightness” Booster for Next-Generation OLEDs

Within the OLED stack is the emissive layer. This is where the light is made. Within the layer are Red, Green and Blue pixels. By combining all three, the full color gamut is rendered in the display. The Green pixel influences brightness. It accounts for as much as 25 percent of the OLED stack costs.

CYNORA’s CEO, Adam Kablanian, commented: “We set out to innovate a differentiated new technology that would enable display leaders to leapfrog beyond legacy emitter solutions for next-generation OLEDs. We believed that TADF was the most promising approach. We knew that with the right blend of advanced technologies and chemistry expertise, the breakthrough was achievable. Our talented team has confirmed the commercial capability of the TADF emitter technology, which has the ability to offer customers substantial savings. The kits are now ready for customer testing and verification.”

GEM: CYNORA’s Materials Discovery Advantage

Behind the cyUltimateGreen product is CYNORA’s Generative Exploration Model (GEM). GEM is the materials discovery engine pioneered by CYNORA to identify with extreme precision the most relevant and useful molecules, and related combinations, from an infinite source of chemical molecules.

GEM combines two key elements: artificial intelligence (AI) and the brainpower of CYNORA’s chemists. While AI offers immense computational capabilities, there can be prediction errors and other uncertainties that diminish the output of useful data for specialized applications. GEM supercharges AI for OLED materials discovery by pairing its computing power with the materials expertise and OLED device knowledge of CYNORA’s chemists to identify molecules with high potential. From there, a scoring system predicts how closely the molecule conforms to must-have parameters, as well as its usefulness for the target purpose – in this case, high-efficiency emitter materials.

GEM strengthened CYNORA’s discovery and synthesis capabilities, and fast-tracked completion of the cyUltimateGreen product, said CTO, Dr. Jan Richter. “Given that the universe of chemical molecules is infinite, identifying the most relevant molecules is exceedingly tough,” he said. “While AI gives us a powerful discovery acceleration tool, our imperative isn’t just to find molecules that are a theoretical fit; they must also be chemically synthesizable. That’s where CYNORA’s chemistry expertise provides the value add.”

The expertise extends to CYNORA technologists’ deep knowledge of the full OLED device. This helped the company engineer the cyUltimateGreen to meet mass-production requirements, without requiring display leaders to make expensive alterations to their manufacturing lines. Essential details like matching evaporation temperatures to meet current device architectures, and aligning material parameters (like energy levels), were part of the calculations. To further reduce cost, integration factors were also considered, like how to manufacture the product within existing hardware and process frameworks without requiring extra evaporation chambers.

Richter added: “TADF technology is igniting a new innovation trajectory for OLED emitter materials. We’re excited to lead with our cyUltimateGreen product.”

For information on CYNORA GmbH, please visit www.cynora.com

cyUltimateGreen is a trademark of CYNORA GmbH

Social Media:

https://facebook.com/cynoragmbh

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol

Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release

Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a

Andersen Consulting styrker sit cybersikkerhedstilbud gennem samarbejde med Trillium Information Security Systems21.3.2026 02:16:00 CET | Pressemeddelelse

Andersen Consulting udbygger sine kompetencer inden for teknologi og risikostyring gennem en samarbejdsaftale med Trillium Information Security Systems (TISS), et cybersikkerhedsfirma. Med en tilstedeværelse i Canada og Pakistan leverer TISS omfattende cybersikkerhedsløsninger til organisationer inden for finans, telekommunikation og den offentlige sektor. Virksomhedens team tilbyder et bredt udvalg af ydelser, herunder sikkerhedsvurderinger, managed security operations, red team-tjenester, digital efterforskning og hændelsesrespons samt GRC-rådgivning. Med næsten to årtiers erfaring leverer TISS adaptive, efterretningsdrevne forsvarsmekanismer, der hjælper kunder med at forudse og reagere på cybertrusler, der er i konstant udvikling. "Hos TISS arbejder vi på at skabe et mere sikkert digitalt miljø ved at give organisationer mulighed for at operere sikkert og med selvtillid," udtalte Mahir Mohsin Sheikh, administrerende direktør for TISS. "Vores samarbejde med Andersen Consulting giver

Andersen Consulting udvider sin teknologiplatform i Frankrig20.3.2026 17:28:00 CET | Pressemeddelelse

Andersen Consulting udvider sit udbud inden for digital transformation med en samarbejdsaftale med Teolia Consulting, et fransk firma, der specialiserer sig i projekt- og produktstyring, cloud-platformsudvikling, datatransformation samt implementering og brug af Atlassian-pakken. Teolia Consulting blev grundlagt i 2014 og hjælper organisationer med at opnå digital performance, fra agile metoder til løsninger, der reducerer lanceringstiden. Virksomhedens ekspertise består i at levere integrerede strategier, der bringer teknologi og organisatorisk forandring i overensstemmelse. Virksomheden arbejder på tværs af brancher, herunder inden for bank- og finanssektoren, forsikring, mode og detailhandel, og hjælper kunder med at få større robusthed og accelerere deres digitale modenhed. "Hos Teolia Consulting mener vi, at ægte transformation opstår, når teknologi og mennesker udvikler sig sammen," sagde Lucienne Jacquet, der er administrerende partner i Teolia. "Ved at samarbejde med Andersen C

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 15:00:00 CET | Press release

- New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted - Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye